Jean-Francois Formela is a Partner at Atlas Venture, which he joined in 1993 to establish the firm's U.S. life sciences practice, and focuses on novel drug discovery technologies and therapeutics. He co-founded Intellia Therapeutics, serving on its board from May 2014 until June 2023, and co-founded Korro Bio and IFM Therapeutics. He currently serves on the boards of IFM Therapeutics, Korro Bio, Antares Therapeutics and Triveni Bio. He holds an M.D. from Paris University School of Medicine and an M.B.A. from Columbia University.
Education
M.D., Paris University School of Medicine
M.B.A., Columbia University
Notable Investments
IFM TherapeuticsKorro Bio KRROTriveni BioAntares TherapeuticsIntellia Therapeutics NTLA
Board Seats
IFM Therapeutics
Korro Bio
Antares Therapeutics
Triveni Bio
Career Timeline
1993
Joined Atlas Venture to establish the firm's U.S. life sciences practice.
2014
Co-founded Intellia Therapeutics and joined its board of directors in May 2014.
2016
Became chairman of the board of IFM Therapeutics when Atlas Venture and Abingworth led its 27 million dollar Series A.
2020
Co-founded Korro Bio, which closed a 91.5 million dollar Series A financing.
2023
Retired from the Intellia Therapeutics board of directors effective June 15.
2023
Became board chair of Triveni Bio at its 92 million dollar Series A launch.